DEXRAZOXANE HYDROCHLORIDE

Post-LOE

dexrazoxane for injection

Gland Pharma

ANDAINJECTIONINJECTABLE

Approved

Nov 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

DEXRAZOXANE HYDROCHLORIDE (dexrazoxane for injection) by Gland Pharma is understood. Approved for breast cancer. First approved in 2016.

Drug data last refreshed 22h ago

Mechanism of Action

understood. Dexrazoxane is a cyclic derivative of EDTA that penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part,…

Indications (1)

breast cancer

Company

Worked on DEXRAZOXANE HYDROCHLORIDE at Gland Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.